Australian Clinical Labs Limited
Australian Clinical Labs Limited
- P/E ratio
- 26.94
Your view on ACL.AX
Overview
What the company does, where it operates, and who runs it.
About Australian Clinical Labs Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Melinda McGrath
- Headquarters
- 1868-1892 Dandenong Road, Clayton, VIC, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Melinda McGrath
- Headquarters
- 1868-1892 Dandenong Road, Clayton, VIC, AU
Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening.
Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services.
ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation.
The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Australian Clinical Labs Limited from FRC's valuation model, read against the market price. ACL.AX last traded at AUD 2.38, 26.9× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Australian Clinical Labs Limited. Starting points for Australian Clinical Labs Limited: P/E 26.9, EPS AUD 0.12, beta 0.82 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Australian Clinical Labs Limited. Australian Clinical Labs Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Australian Clinical Labs Limited. Trailing twelve-month EPS for Australian Clinical Labs Limited stands at AUD 0.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrSep 2025 | Next QtrDec 2025 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | AUD 0.00 | AUD 0.07 | AUD 0.19 | AUD 0.21 |
| Low estimate | AUD 0.00 | AUD 0.07 | AUD 0.19 | AUD 0.20 |
| High estimate | AUD 0.00 | AUD 0.07 | AUD 0.20 | AUD 0.22 |
| No. of analysts | 0 | 1 | 6 | 6 |
| Year-ago EPS | — | — | AUD 0.12 | — |
| Growth | — | — | +59.4% | — |
Revenue Estimate
| Revenue | Current QtrSep 2025 | Next QtrDec 2025 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | AUD 386.06M | AUD 378.48M | AUD 758.06M | AUD 788.71M |
| Low estimate | AUD 386.06M | AUD 378.48M | AUD 754.57M | AUD 777.71M |
| High estimate | AUD 386.06M | AUD 378.48M | AUD 762.99M | AUD 800.78M |
| No. of analysts | 2 | 1 | 7 | 7 |
| Year-ago revenue | — | — | AUD 729.52M | — |
| Growth | — | — | +3.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Australian Clinical Labs Limited. Australian Clinical Labs Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| BDX.AXBCAL Diagnostics Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| CTE.AXCryosite Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| GSS.AXGenetic Signatures Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| HLS.AXHealius Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| IIQ.AXINOVIQ Ltd | Healthcare | Medical - Diagnostics & Research | — | ||
| RHY.AXRhythm Biosciences Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| SHL.AXSonic Healthcare Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ILMNIllumina, Inc. | Healthcare | NASDAQ | $31.8B | ||
| IMDXInsight Molecular Diagnostics Inc. | Healthcare | NASDAQ | $52.1M | ||
| IME.AXImExHS Limited | Healthcare | ASX | — | ||
| IMMVFImmunovia AB (publ) | Healthcare | OTC | $6.1M | ||
| IQVIQVIA Holdings Inc. | Healthcare | NYSE | $42.5B | ||
| ISPCiSpecimen Inc. | Healthcare | NASDAQ | $1.3M | ||
| IVROInVitro International | Healthcare | OTC | $1.8M | ||
| IZO.CNIzotropic Corporation | Healthcare | CNQ | $20.6M | ||
| IZOZFIzotropic Corporation | Healthcare | OTC | $11.9M | ||
| JMPHFLeveljump Healthcare Corp. | Healthcare | OTC | $15.2M | ||
| LDDDLongduoduo Company Limited | Healthcare | OTC | $15.3M | ||
| LHLabcorp Holdings Inc. | Healthcare | NYSE | $30.1B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $11.6B in assets | 0.01% | |
| SCHCSchwab International Small-Cap Equity ETF | $5.4B in assets | 0.02% | |
| DDLSWisdomTree Dynamic International SmallCap Equity ETF | $410M in assets | 0.06% | |
| DTHWisdomTree International High Dividend Fund | $635M in assets | 0.02% | |
| AVDSAvantis International Small Cap Equity ETF | $379M in assets | 0.02% | |
| DWMWisdomTree International Equity Fund | $651M in assets | 0.01% | |
Largest holders first, then the funds most concentrated in ACL.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Australian Clinical Labs Limited. Coverage tracks Australian Clinical Labs Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Australian Clinical Labs Limited.